Multicenter Study to Assess Endoscopic Resection of 159 Sinonasal Adenocarcinomas

Abstract

The endoscopic approach seems to be efficient to remove sinonasal adenocarcinoma with low morbidity.

Intestinal type adenocarcinoma of the ethmoid: Outcomes of a treatment regimen based on endoscopic surgery with or without radiotherapy

“…In fact, data from an international collaborative study on anterior craniofacial resection clearly showed that, even in expert hands, the procedure is associated with non‐negligible mortality (4.7%) and morbidity (36.3%) . Conversely, no mortality was observed in either our series or other large series of ethmoid adenocarcinoma in which endoscopic surgery was used. Furthermore, complications occurred in 17.1% of our patients.…”

“…The comparative analysis of survival data show remarkable similarities. Five‐year OS was 68.8% in our series and 62% and 68% in the studies of Vergez et al (2013) and Camp et al (2014), respectively. Comparable rates of 5‐year event‐free survival were observed herein (71.7%) and in the French study (74%) .…”

Postoperative Correlation of Radiological and Surgical Findings in Management of Ethmoid Sinus Adenocarcinoma

“…The low recidivism rates found in recent studies by Vergez et al [14] (17.6%) and Nicolai et al [8] (21.3%) compared with the common literature (30% on average) and in our study (33.3%) can be explained in part by the presence of smaller populations in their populations of advanced tumor stages (26.1% % Of tumors classifi ed T4 for Vergez and al., 32% of T4 tumors for Nicolai and al., 37.5% in our population). The tumor recurrence rate thus appears to be directly correlated with the initial stage of the tumor, the authors with the lowest recurrence rate being those with the least number of advanced tumors.…”

Timing of surgery and adjuvant radiation therapy for sinonasal malignancies: Effect of surgical approach

“…[7][8][9][10] Open surgery requires a facial incision and for those undergoing craniofacial resection, a craniotomy. [12][13][14][15][16][17][18][19] Recent studies have reported that delays in treatment for head and neck cancers 20 are associated with clinical-topathologic upstaging and inferior survival. [9][10][11] As a result, for the properly selected candidate, an This study was presented at the 2019 North American Skull Base Meeting, Orlando, Florida.…”